Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs.
Christopher M BoothElizabeth A EisenhauerBishal GyawaliIan F TannockPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Keyphrases